Objectives To conduct a systematic review of tranexamic acid (TXA) and the risk of renal
failure from urinary clots in adult patients with hematuria. Methods A systematic review of …

In a Review published in the March 2007 issue of the journal, Hedges and colleagues
described the existing options to prevent or treat uremic bleeding. Their article did not …

There is little information on the characteristics, management, or sequelae of gross
hematuria in autosomal dominant polycystic kidney disease (ADPKD). Therefore, we …

Background: Although hypertension is commonly found in patients with autosomal dominant
polycystic kidney disease (ADPKD), there is no consensus about which antihypertensive …

Nephrolithiasis is an important manifestation of autosomal dominant polycystic kidney
disease (ADPKD), which occurs in approximately 20% of patients. It should always enter the …

Autosomal dominant polycystic kidney disease (ADPKD) is considered the most common
inherited form of kidney disease across all ethnic types (1-3). Present understanding holds …

Aim Tranexamic acid (TXA) is a synthetic anti‐fibrinolytic agent commonly used for the
prevention and treatment of bleeding disorders. The aim of this study is to describe the …

ABSTRACT Introduction: Autosomal Recessive Polycystic Kidney Disease (ARPKD) is an
important pediatric cause of morbidity and mortality, with a variable clinical spectrum …

Background There are limited therapeutic options to slow the progression of autosomal
dominant polycystic kidney disease (ADPKD). Recent clinical studies indicate that …

Causes of haematuria in adult polycystic kidney disease | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …